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Background
Epilepsy is an important cause of chronic disability and a pre-
ventable cause of early mortality in low- and middle-income 
countries (LMICs). More than 1% of the population in LMICs, 
>60 million people, suffers from epilepsy1. Phenobarbital, the 
oldest antiepileptic medication still in use today, was discov-
ered in 1912. Phenobarbital costs 1 to 2 US cents per day or 
<5 USD per year and remains the drug of choice for several 
presentations of epilepsy. Four additional older antiepileptic 
drugs are commonly found on the World Health Organization’s 
Essential Medicines List and typically cost <50 cents per day.
Epilepsy is an exemplary disease for health systems plan-
ning for brain disorders. Epilepsy presents across the lifespan, 
with the predominance of first presentations in childhood and 
in the elderly. The stigma of epilepsy, including its formal 
and informal prohibitions on school attendance, employment, 
and marriage in some societies, emphasizes it as an important 
challenge for the global public health community. Medically, 
it represents a final common manifestation of a myriad of 
possible causes: genetic conditions, developmental conditions, 
central nervous system infections, head trauma, stroke, and 
sometimes defies clear explanation of its etiology. This is typi-
cal of several neurological disorders in which etiologies may 
reflect the so-called “triple burden” of communicable, noncom-
municable, and traumatic disorders. Access to diagnostic services 
for epilepsy, such as electroencephalogram and neuroimaging, 
enhances the diagnostic clarity of epilepsy, but the absence of 
infrastructure in LMICs does not preclude antiepileptic medica-
tion treatment. Women of childbearing potential represent a spe-
cial treatment group since some antiepileptic medications should 
be avoided during pregnancy, especially valproic acid, given 
the risk of this medication causing congenital malformations 
including neural tube defects.
Updating the approach to epilepsy treatment: a 
cascade of care
Prior framing of the global epilepsy challenge was through the 
epilepsy treatment gap2, or the number of people with epilepsy 
(PWE) who are eligible for but not taking an antiepileptic medi-
cation. This gap reaches up to 90% in LMICs3,4. Meanwhile, a 
“zero” treatment gap remains unattainable, even in high-income 
settings. In this way, “getting to zero” is not a realistic goal 
for epilepsy care as it would be for infectious diseases, which 
could be eliminated or even eradicated.
Using the treatment gap approach, essential steps in the care 
pathway of PWE have been overlooked. Since epilepsy is both 
a clinical problem and a matter of global policy, it requires met-
rics to optimize care and achieve population-based outcomes. 
Although countries may be meeting treatment gap goals, many 
PWE are not adequately diagnosed by seizure type. Some are 
treated with an inappropriate choice of antiepileptic medica-
tion. And in spite of adequate medication adherence, seizure 
freedom for many PWE may be difficult to attain due to 
inadequate dosing as well as limited quality and inconsistent 
supplies of antiepileptic medications4–7.
As HIV prevalence rates drop in many countries, epilepsy may 
be more prevalent in many countries than HIV/AIDS. People 
living with HIV/AIDS have benefitted from global advocacy, 
political will, and dedicated and sustained financial invest-
ments. Private-public partnerships and supranational agencies 
have brought light to the extreme tragedy of the HIV epidemic. 
This was achieved in spite of the stigma of HIV/AIDS and 
the disproportionate burden of HIV/AIDS in resource-limited 
settings and vulnerable populations. 
The same efforts have not been made in epilepsy, an ancient 
disease, that can learn from the progress of HIV/AIDS. Build-
ing upon the successes of global policymaking for HIV/AIDS 
and creating a framework for countries and organizations to 
monitor progress in epilepsy care will help organize and justify 
novel programming. It may not achieve the stature of HIV/AIDS 
programming, but a framework for thinking about progress in 
epilepsy care pathways can be realized. Given the clarity of the 
HIV/AIDS care continuum model and the UNAIDS 90-90-90 
targets, I propose this same approach to the cascade of care8 
could be used as a viable framework for PWE. In the HIV 
model, the targets of success include (1) ensuring 90% of all 
people with HIV infection know they are infected, (2) starting 
90% of infected people on antiretroviral therapy, and (3) achiev-
ing viral suppression in 90% of those treated. At least 90% of all 
people with HIV are also linked to and retained in care.
(1)    Diagnosis of epilepsy allows patients to be success-
fully given their medical diagnosis, distinct from 
supernatural causes but also distinct from primary 
psychiatric behavioral events, cardiac dysrhythmias, 
symptomatic hypoglycemia, and related conditions.
(2)    Linkage to epilepsy care allows the establishment and 
organization of services for PWE - and the minimum 
standards for epilepsy care - including medication 
management, as well as access to neuroimaging, EEG 
services, and/or supportive laboratory studies such 
as antiepileptic drug levels9.
(3)    Antiepileptic medication treatment enables the man-
agement of seizures through efficacious, appropriately 
chosen and prescribed, available, accessible, and afford-
able medicines.
(4)    Seizure control and freedom requires the antiepilep-
tic medication or, in some cases, multiple medica-
tions to effectively reduce the number of seizures, 
ideally to zero in at least 2/3 of PWE10, and increase 
the number of seizure-free days. Although not 
explicitly required, minimization of side effects such as 
sedation, would be optimal.
This cascade of epilepsy care should have globally agreed 
targets, likely 90% of PWE being diagnosed; 90% of PWE 
linked and retained in care for epilepsy; and 90% of PWE who 
need an AED receiving it. In addition, a reasonable goal of 
70% of all PWE achieving seizure control should be targeted. 
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This provides a fair comparison for services across higher and 
lower income settings and may indeed reflect, like in HIV/
AIDS, that lower income countries are better able to implement 
cascades of care for more of their population. Although these 
precise numbers may be debated by the global community, they 
are goals that reflect actual processes of epilepsy care.
There are several barriers to measuring and realizing these 
metrics.
(1)    Diagnosis of epilepsy can best be measured through 
community-based surveys in the population asking key 
survey questions. The lack of a distinct biomarker for 
epilepsy, such as a laboratory test, makes measurement 
often depend on semi-skilled providers.
(2)     Linkage to epilepsy care is perhaps the most difficult 
step in the care pathway since it requires functionality 
of the health care system that will not be overwhelmed 
by new referrals or under-prepared to deal with a 
potential influx of patients if diagnoses are made. 
(3)    Antiepileptic medication treatment is realizable but 
there are insufficient efforts to make medications uni-
versally available, accessible, and affordable. Treatment 
of at least 70% of PWE will require non-governmental 
organizations, governments, supranational organizations, 
and patients. Barriers to realization of medication pro-
vision in 2019 remain common including out-of-date 
essential medicines lists, the variable quality of medi-
cation supplies in LMICs, lack of appropriate supply 
chains, excessive regulations on some medications, and 
high out-of-pocket costs to patients.
(3)    Seizure control and freedom are both scientific and edu-
cational challenges. Barriers to achieving this metric 
include expertise on dosing medications, choosing 
medications appropriately, and having the time and 
resources to adequately educate patients. It requires 
addressing causes of medication-resistant epilepsy 
including preventable causes such as neurocysticercosis, 
vaccine-preventable perinatal infections, and many 
cases of preterm birth. It includes changing the behav-
ioral pattern of taking a drug temporarily, as is common 
for an infectious disease, to taking a medication 
constantly and potentially lifelong. Additional barriers 
include the lack of epilepsy surgery opportunities for 
many LMICs and lack of access to an expanded list of 
newer scientifically proven antiepileptic medications.
Conclusions
Epilepsy is a medically complex and historically poorly understood 
condition across cultures worldwide. In lower-income countries, 
neurologists are present in staggeringly low proportions. How-
ever, the metrics of achievement for epilepsy care can be made 
clearer and therefore can become achievable. Disaggregating 
the barriers to epilepsy treatment can inform the implementation 
of solutions and ultimately come full circle and “close” the more 
familiar “epilepsy treatment gap.”
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I agree with the reviewer here. More than enthusiasm and recognition will be needed; dedicated
and sustained funding are requisite. I have a sentence to this effect in the revised manuscript. This
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I am trying not to focus on any one particular country in this position piece although I recognize
some regions in some countries have made major progress. I now cite the WHO Information Kit on






Although the WHO and its publications have been thought leaders for epilepsy, the
recommendations are arguably insufficient. More can be done. Compared to other neurological
diseases, such as poliomyelitis which have global campaigns backed by weekly updates,
websites, multilateral partnerships, and governmental and supranational prioritization, I believe









I would suggest dementia and cognitive decline as one. Another could be neurodevelopmental
delay. Another – to less extent – could be cerebrovascular disease. One may argue these have
communicable, noncommunicable, and traumatic risk factors. I understand the reviewer’s point




Yes, there is no one definitive biomarker like in AIDS. The movement from a single virus to a
neurological disorder is a challenge. Yet, the public health understanding of a high-prevalence,
global, life-threatening condition, subject to stigma and in need of global attention made me wish to
compare these two. This line of thinking is more of a public health and stakeholder perspective
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That is true. However, cost is a matter of negotiation for some of these drugs rather than the
scientific challenge; so that could be the next round of measured metrics – i.e. out of pocket
payments and catastrophic health expenditures by people with epilepsy. I suspect I am similar to
the reviewer here in that I am of the opinion that this is a solvable problem. With enough funding,
political will, private-public partnerships, and increased and unrelenting advocacy of our
community, surmountable barriers for epilepsy care could be overcome and the evidence base
 could be expanded to better address these issues.
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I agree with this statement.  In order to not over-state the HIV/AIDS field’s achievements, I have
used words such as “progress” instead of “success.” Although scientific and policy efforts have not
prevented or cured HIV/AIDS and there remain many million people infected globally, the
counterfactual situation to this pandemic being unaddressed is even worse. Although the work is
by no means complete, especially for locations like Sub-Saharan Africa, there is much to be
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This is almost certainly correct and in fact I have thought about this issue a great deal in recent
work published on traditional medicine and epilepsy in Guinea and in Bhutan. This is a
cross-cultural and international issue. As such, I have added a new statement on the barriers to
epilepsy diagnosis in this paper and thank the reviewer for emphasizing this major challenge. I also






This is certainly the case in multiple geographic locations. The workforce and drug supply are
additional metrics that need to be measured and could be part of an expanded framework, beyond
the 90-90-90 (or 90-90-70 approach). The data on colonization and mistrust is a bit less clear and
less available in the literature. Although there are definitely reports on mistrust, the literature is
limited and this becomes harder for me to cite. Also, I wanted to avoid focusing on any one






Thank you for your ideas. I emphasize HCP and medications more in the revision. I hope this piece
opens up a larger conversation on global epilepsy, an under-discussed topic compared to its
 substantial (and likely growing) burden.
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